Advertisement Multicare to market Sanofi-aventis Solian, Stilnox in Philippines - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Multicare to market Sanofi-aventis Solian, Stilnox in Philippines

Multicare Pharmaceuticals, the Philippines subsidiary of Lupin, is set to market and distribute Sanofi-Aventis' central nervous system (CNS) global brands Solian (Amisulpride) and Stilnox (Zolpidem Hemitartrate) in the Philippines.

Solian is indicated as a treatment for acute and chronic schizophrenia characterized by both negative and positive symptoms, while Stilnox is used for the treatment of insomnia and sleep disorders.

Under the contract, the products will be marketed by Multicare’s CNS Business Unit.

Multicare president Romey Sy said Multicare has four key strategic business units focused on Women’s Health, Pediatrics, Respiratory, GI, Diabetes Care & CNS.